clinical trial · NCT06846554
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
Pulmonary Arterial HypertensionAPL-9796APL-9796
brief summary
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).
started
Apr 9, 2025
primary completion
Aug 30, 2027
completion
Sep 30, 2027
last updated
Mar 4, 2026
official title
A Phase 2, Multicentre, Open-Label Trial to Evaluate APL-9796 in Adult Participants With Pulmonary Hypertension (ViTAL-PH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol